Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05434858` - Imagery as Biomarker of Gout	N/A
Completed	`NCT04060173` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671	Phase 1
Recruiting	`NCT05504083` - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients	Phase 2
Completed	`NCT04966325` - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects	Early Phase 1
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT00995618` - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia	Phase 2
Completed	`NCT00288158` - Primary Prevention of Hypertension in Obese Adolescents	Phase 2
Terminated	`NCT04987294` - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease	Phase 2
Completed	`NCT04236219` - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers	Phase 1
Completed	`NCT06189404` - Effect of Tigulixostat on the Pharmacokinetics of Theophylline	Phase 1
Recruiting	`NCT05586958` - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients	Phase 3
Recruiting	`NCT06084585` - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia	N/A
Recruiting	`NCT06056570` - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia	Phase 1/Phase 2
Not yet recruiting	`NCT04586803` - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers	Phase 1
Completed	`NCT02959918` - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid	Phase 2
Not yet recruiting	`NCT02944214` - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients	N/A
Completed	`NCT02557126` - Study of URC102 to Assess the Safety and Efficacy in Gout Patients	Phase 2
Active, not recruiting	`NCT01021241` - Safety and Efficacy Study of Intravenous Uricase-PEG 20	Phase 1
Completed	`NCT00756964` - Lowering Serum Uric Acid to Prevent Acute Kidney Injury	Phase 2
Terminated	`NCT00607152` - Rasburicase (Fasturtec) Registration Trial	Phase 3

NCT number	NCT06168929
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	December 13, 2023
Completion date	January 13, 2024

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms